IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8957089 B1

PDFFull Text
Date of Patent:
Feb. 17, 2015

Filed:

Mar. 10, 2013

Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy

Applicants:

Abbvie Deutschland Gmbh & Co. KG, Wiesbaden, DE;

Abbvie Inc., North Chicago, IL (US);

Inventors:

Wilhelm Amberg, Wiesbaden, DE;

Michael Ochse, Wiesbaden, DE;

Udo Lange, Mannheim, DE;

Wilfried Braje, Wiesbaden, DE;

Berthold Behl, Wiesbaden, DE;

Wilfried Hornberger, Wiesbaden, DE;

Mario Mezler, Wiesbaden, DE;

Charles Hutchins, Green Oaks, IL (US);

Assignees:

AbbVie Deutschland GmbH & Co. KG, Wiesbaden, DE;

AbbVie Inc., North Chicago, IL (US);

Attorneys:

Lisa V. Mueller

Michael Best & Friedrich LLP

Primary Examiner:

Zinna Northington Davis

Int. Cl.
CPC ...
C07D 217/18 (2006.01); C07D 401/04 (2006.01); A61K 31/44 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 409/12 (2006.01); C07D 409/14 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 498/04 (2006.01); C07D 513/04 (2006.01); C07D 401/08 (2006.01);
U.S. Cl.
CPC ...
C07D 217/18 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 498/04 (2013.01); C07D 513/04 (2013.01); C07D 401/08 (2013.01);
Abstract

The present invention relates to tetrahydroisoquinoline of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such tetrahydroisoquinolines, and the use of such tetrahydroisoquinolines for therapeutic purposes. The tetrahydroisoquinolines are GlyT1 inhibitors.

Find Patent Forward Citations

Loading…